

Exome Sequencing Reveals *RAG1* Mutations in a Child with Autoimmunity and Sterile Chronic Multifocal Osteomyelitis Evolving into Disseminated Granulomatous Disease

Andreas Reiff · Alexander G. Bassuk · Joseph A. Church · Elizabeth Campbell · Xinyu Bing · Polly J. Ferguson

Received: 27 March 2013 / Accepted: 3 October 2013 / Published online: 12 October 2013
© Springer Science+Business Media New York 2013

Abstract We describe a boy who developed autoinflammatory (chronic sterile multifocal osteomyelitis) and autoimmune (autoimmune cytopenias; vitiligo) phenotypes who subsequently developed disseminated granulomatous disease. Whole exome sequencing revealed homozygous *RAG1* mutations thus expanding the spectrum of combined immunodeficiency with autoimmunity and granuloma that can occur with RAG deficiency.

Keywords Granulomatous disease · chronic recurrent multifocal osteomyelitis (CRMO) · immune deficiency · recombinaise activating gene (RAG) · autoimmune hemolytic anemia

Mutations in the recombinaise-activating gene (RAG) 1 or 2 can lead to a range of phenotypes including classic severe combined immune deficiency (SCID; OMIM # 601457) [1], Omenn syndrome (OMIM# 603554) [2, 3] as well as milder immune deficiency. Patients with hypomorphic *RAG1* mutations may

present with a combination of increased susceptibility to infections and autoimmunity [4–7] or granulomatous disease [7–9]. These hypomorphic mutations result in decreased RAG1 activity, the production of low-affinity self-reactive antibodies, increased autoantibody production and moderate immune deficiency [6]. Autoimmune hemolytic anemia (AIHA), autoimmune neutropenia, idiopathic thrombocytopenic purpura, vitiligo, psoriasis, Guillian-Barre syndrome and granulomatous dermatitis have been reported [7].

Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory bone disorder that presents with sterile osteomyelitis, with or without granulomas and is frequently associated with psoriasis and Crohn disease [10–13]. Anti-inflammatories provide clinical improvement while antimicrobials are ineffective. There is no known relationship to immune deficiency and the pathogenesis remains unknown, but there are two autosomal recessive forms of CRMO that are due to dysregulation of the IL-1 pathway [14–17].

Our patient was a Lebanese boy born to first cousins who presented at age 10 months with otitis media, fever, ankle swelling and rash. He took aspirin for 1 month and did well until 17 months of age when he was admitted with otitis media, pallor and splenomegaly. His hemoglobin was 5.9, platelets 62 K, WBC was 5.6 K (ANC of 1680, ALC 2184, AEC 728) and ESR was 122 mm/hr. He had a positive Coombs' test, positive ANA and an equivocal anti-dsDNA. Despite treatment with IVIG 2 g/kg/month he required up to 2 mg/kg/day of prednisone to control his AIHA. At age 5, he developed vitiligo. From 3–5 years of age, while on daily steroids, he developed uncomplicated varicella, and 2 pneumonias. Serum immunoglobulins were normal.

At age 6, he sustained pathologic fractures of the ulna and olecranon. A bone scan revealed uptake in the distal humerus,

A. Reiff · J. A. Church
The Department of Pediatrics, Children's Hospital Los Angeles and the Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

A. G. Bassuk · E. Campbell · X. Bing · P. J. Ferguson
The Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA

P. J. Ferguson (✉)
Department of Pediatrics, Division of Rheumatology,
University of Iowa Carver College of Medicine, 200 Hawkins Drive,
4038 Boyd Tower, Iowa City, IA 52240, USA
e-mail: polly-ferguson@uiowa.edu

proximal ulna, proximal tibia and calcaneus. Olecranon biopsy revealed necrotizing granulomatous inflammation and bone necrosis, fibrosis and chronic inflammation; calcaneal biopsy revealed marrow fibrosis, chronic inflammation but no granulomas. Cultures and stains for bacteria, mycobacteria and fungi were negative. He was treated empirically for mycobacteriosis with isoniazide, ethambutol, pyrazinamide and rifampicin, which was stopped 4 months later due to a lack of efficacy. He improved on steroids.

At 9 years of age, he presented with an erythematous wrist mass and worsening multifocal bone lesions; biopsy revealed sterile necrotizing granulomatous inflammation of the subcutaneous tissue. Chest imaging was concerning for early interstitial lung disease. Plain radiographs and MRI of the right ankle revealed lytic bone lesions (Fig. 1). Biopsy of the fibula revealed sterile necrotizing granulomatous inflammation. Serologic and antigen testing for *Toxoplasma*, *Bartonella*, *Brucella*, *Coccidioides*, *Cryptococcus*, *Histoplasma*, *Aspergillus*, *Syphilis*, *CMV*, *EBV*, *Pneumocystis*, *Legionella*, *Mycoplasma* and *Chlamydia* were negative. Treatment for mycobacteriosis was

reinitiated with clarithromycin, ethambutol and moxifloxacin without improvement. Immunologic assessment revealed elevated serum IgG [2480 mg/dL (423–1187)] and IgA [381 mg/dL (22–157)] with a normal IgM and IgE. He made protective antibody titers to tetanus, varicella and polio virus but poor responses to pneumococcal antigens. Reassessment of response to immunization with 23-valent pneumococcal vaccination was not performed due to continued immune suppressive drug regimens. When tested at ages 9 and 10 years, he made normal T cell lymphoproliferative responses to PWM, ConA, VZV, tetanus; equivocal responses to candida and CMV and negative responses to Herpes simplex virus and Adenovirus. Lymphocyte populations revealed T and B cell lymphopenia with low absolute and relative numbers of CD3 [250; 29 %], CD3+CD4+ [109; 18 %], CD3+CD8+ [26; 5 %], CD19+ [96; 11 %], CD20+ [71; 9 %] cells with an absolute and relative increase in CD3-CD16+CD56+ NK cells [369; 62 %] collected while on corticosteroids. No studies on T cell receptor repertoire diversity were performed. His Nitroblue tetrazolium assay was normal.

Fig. 1 Multifocal Osteomyelitis. Plain radiograph demonstrate progressive osteolytic lesions in the right distal radius and ulna over 4 months (a,b) at age 9. Progressive destruction of the olecranon (c,d) and right distal tibia/fibula (e,f) from age 9–11 years which are accompanied by diffuse osteolytic T1 hypointense (g), T2 hyperintense (h) lesions on MRI



Between 10–12 years of age, he developed recurrent AIHA, non-granulomatous anterior uveitis and diffuse sterile non-caseating granulomatous disease of his lungs, bone marrow, testis, liver and pancreas. Immunologic studies showed worsening hypergammaglobulinemia [IgG of 3340 mg/dL], with improved T cell numbers but continued B cell lymphopenia: CD3 [943; 50 %], CD3+CD4+ [850; 45 %], CD3+CD8+ [89; 5 %], CD19+ [90; 5 %], CD20+ [4 %] cells with a continued absolute and relative increase in CD3-CD16+CD56+ NK cells [917; 44 %]. Treatment with rituximab resulted in no improvement in the diffuse granulomatous disease, but his AIHA did improve. Treatment with infliximab at 10 mg/kg/dose was associated with significant improvement in his lung disease with partial improvement in his bone lesions. At the age of 12, he developed a diffuse erythematous rash. Histology showed dense lymphohistiocytic dermal infiltrate with a thin layer of parakeratosis, multifocal spongiosis without acanthosis, eosinophils or granulomas in the epidermis. At age 11 he succumbed to rapidly progressive pneumonia due to H1N1 infection with ARDS and subsequent multi-organ system failure. It was unclear if infection or uncontrolled innate immune system activation was the primary factor in his death.

Whole exome sequencing was performed on DNA from the child and both parents and was analyzed for variations that were homozygous in the child, heterozygous in both parents and not in dbSNP, 1000 genomes or the Exome Variant Server [<http://evs.gs.washington.edu/EVS/>] [18]. This led to the identification of non-synonymous variations in 12 genes (*RBM15*, *C1orf111*, *OBSCN*, *PDS5A*, *PCDHA2*, *ANKRD26*, *RAG1*, *HEPHE1*, *DNAH3*, *KLKBL4*, *ZNF208*). Only *RAG1* mutations have been associated with autoimmune cytopenia, vitiligo and sterile granulomatous disease [7]. The c.2095C>T *RAG1* variation was verified by Sanger resequencing as homozygous in the affected child; heterozygous in both parents, heterozygous in one sibling and absent in the other sibling. PolyPhen-2 v2.2.2r398 predicts the p.Arg699Trp variant protein to be probably damaging [<http://genetics.bwh.harvard.edu/ggi/pph2>]. This mutation is in the heptamer binding region of *RAG1* which has been previously reported in a compound heterozygous state in a patient with Omenn syndrome and a child with autoimmune phenomena [7, 19]. There is no evidence of maternal engraftment as the X chromosome showed uniform homozygosity in the whole exome analysis.

Complete RAG deficiency results in the inability to functionally rearrange T and B cell receptors which results in B and T cell deficiency and hypogammaglobulinemia [20]. Our patient had low but present B and T cells, produced excess levels of IgG and retained the ability to make functional antibody to protein antigens demonstrating that there was residual RAG activity in his lymphocytes. His ability to make NK cells is consistent with RAG deficiency and may be due to

a compensatory expansion in this setting of immune dysregulation [20, 21]. Genetic studies on this boy demonstrated uniform homozygosity on the X chromosome which argues against maternal engraftment as an explanation for the residual RAG function. This supports the conclusion that the p.Arg699Trp mutation only partially disrupts RAG function.

This case is the first report of chronic multifocal osteomyelitis associated with hypomorphic *RAG1* mutations and provides further evidence that primarily rheumatologic symptoms may occur in children with hypomorphic *RAG1* mutations. Corticosteroids and treatment with TNF-alpha antagonists (but not rituximab) improved his lung and bone inflammation, which suggests a role for activated T cells in disease pathogenesis [22–24]. The rash that occurred in this patient shared features with erythroderma seen in Omenn syndrome but lacked acanthosis [25]. This case should alert clinicians to include atypical immune deficiency in the differential diagnosis when recurrent infections and granulomatous inflammation occur in patients with rheumatic disease. Early diagnosis and bone marrow transplant is essential to prevent severe complications of autoimmunity and infections and can be lifesaving [9].

Acknowledgments This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health [1R01AR059703-01A1 PJF and AGB].

References

- Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. *Science*. 1996;274(5284):97–9. Epub 1996/10/04.
- Villa A, Santagata S, Bozzi F, Imberti L, Notarangelo LD. Omenn syndrome: a disorder of Rag1 and Rag2 genes. *J Clin Immunol*. 1999;19(2):87–97. Epub 1999/05/05.
- Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al. Partial V(D)J recombination activity leads to Omenn syndrome. *Cell*. 1998;93(5):885–96. Epub 1998/06/18.
- de Villartay JP, Lim A, Al-Mousa H, Dupont S, Dechanet-Merville J, Coumau-Gatbois E, et al. A novel immunodeficiency associated with hypomorphic *RAG1* mutations and CMV infection. *J Clin Invest*. 2005;115(11):3291–9. Epub 2005/11/09.
- Ehl S, Schwarz K, Enders A, Duffner U, Pannicke U, Kuhr J, et al. A variant of SCID with specific immune responses and predominance of gamma delta T cells. *J Clin Invest*. 2005;115(11):3140–8. Epub 2005/10/08.
- Walter JE, Rucci F, Patrizi L, Recher M, Regenass S, Paganini T, et al. Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. *J Exp Med*. 2010;207(7):1541–54. Epub 2010/06/16.
- Avila EM, Uzel G, Hsu A, Milner JD, Turner ML, Pittaluga S, et al. Highly variable clinical phenotypes of hypomorphic *RAG1* mutations. *Pediatrics*. 2010;126(5):e1248–52. Epub 2010/10/20.
- Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. *N Engl J Med*. 2008;358(19):2030–8. Epub 2008/05/09.
- De Ravin SS, Cowen EW, Zarembek KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can

- cause destructive midline granulomatous disease. *Blood*. 2010;116(8):1263–71. Epub 2010/05/22.
10. Jansson A, Renner ED, Ramser J, Mayer A, Haban M, Meindl A, et al. Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. *Rheumatology (Oxford)*. 2007;46(1):154–60. Epub 2006/06/20.
 11. Bjorksten B, Gustavson KH, Eriksson B, Lindholm A, Nordstrom S. Chronic recurrent multifocal osteomyelitis and pustulosis palmoplantaris. *J Pediatr*. 1978;93(2):227–31.
 12. Laxer RM, Shore AD, Manson D, King S, Silverman ED, Wilmot DM. Chronic recurrent multifocal osteomyelitis and psoriasis—a report of a new association and review of related disorders. *Semin Arthritis Rheum*. 1988;17(4):260–70.
 13. Bognar M, Blake W, Agudelo C. Chronic recurrent multifocal osteomyelitis associated with Crohn’s disease. *Am J Med Sci*. 1998;315(2):133–5.
 14. Ferguson PJ, Chen S, Tayeh MK, Ochoa L, Leal SM, Pelet A, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). *J Med Genet*. 2005;42(7):551–7. Epub 2005/07/05.
 15. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. *N Engl J Med*. 2009;360(23):2426–37. Epub 2009/06/06.
 16. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. *N Engl J Med*. 2009;360(23):2438–44. Epub 2009/06/06.
 17. Herlin T, Fiirgaard B, Bjerre M, Kerndrup G, Hasle H, Bing X, et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. *Ann Rheum Dis*. 2012. Epub 2012/10/23.
 18. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. *Nature*. 2010;467(7319):1061–73. Epub 2010/10/29.
 19. Zhang ZY, Zhao XD, Jiang LP, Liu EM, Cui YX, Wang M, et al. Clinical characteristics and molecular analysis of three Chinese children with Omenn syndrome. *Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol*. 2011;22(5):482–7. Epub 2011/07/21.
 20. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. *Cell*. 1992;68(5):869–77. Epub 1992/03/06.
 21. Menoret S, Fontaniere S, Jantz D, Tesson L, Thinard R, Remy S, et al. Generation of Rag1-knockout immunodeficient rats and mice using engineered meganucleases. *Faseb J*. 2013;27(2):703–11. Epub 2012/11/15.
 22. Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. *Gastroenterology*. 2011;141(6):2026–38. Epub 2011/08/31.
 23. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. *Arthritis Rheum*. 2008;58(5):1248–57. Epub 2008/04/29.
 24. van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. *Gastroenterology*. 2001;121(5):1242–6. Epub 2001/10/26.
 25. Al-Herz W, Nanda A. Skin manifestations in primary immunodeficient children. *Pediatr Dermatol*. 2011;28(5):494–501. Epub 2011/04/02.